Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein pelota homolog (PELO) is a highly conserved cytoplasmic protein, encoded by the PELO gene in humans[1][9]. It belongs to a family of proteins involved in the recognition and rescue of stalled ribosomes during translation, in a process known as ribosome quality control or No-Go Decay (NGD)[2][5][7]. PELO functions with partners such as HBS1L and ABCE1 to dismantle aberrant ribosome complexes, release nascent polypeptide-tRNA, and promote ribosome recycling independent of stop codon recognition[6]. In biological systems, PELO plays important roles in translational surveillance, cell cycle control, spermatogenesis, and adult stem cell self-renewal[1][3][4]. Loss of PELO function leads to defects in spermatogenesis and meiotic arrest in model organisms and can dysregulate translation of proteins critical in hematopoiesis (e.g., the C/EBPα isoform in myeloid cells), connecting PELO indirectly to cancer biology[4]. There is no current evidence that PELO is a direct therapeutic target or that drugs interact with it, and no established biomarker or specific safety concern for its targeting in humans.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein pelota homolog (PELO).